Ingredient or product comparison
GHK-Cu Long Term Studies: Comparison Table
Human Dermatology RCT (2015) 12 months 67 adults, aged 45–65 3% topical cream, daily 37% increase in dermal density at month 12 Mild erythema in 4% (transient) Longest human trial shows sustained benefit without plateau Rat Aging Model (2012) 24 months 40 aged
This source-based comparison does not add ratings or recommend a winner.
- Human Dermatology RCT (2015)
- 12 months
- 67 adults, aged 45–65
- 3% topical cream, daily
- 37% increase in dermal density at month 12
- Mild erythema in 4% (transient)
- Longest human trial shows sustained benefit without plateau
- Rat Aging Model (2012)
- 24 months
- 40 aged rats
- 10mg/kg subQ, 3×/week
- 19% reduction in fibrosis markers; maintained fur density
- None. CBC and liver enzymes normal throughout
- No immune sensitization or chronic toxicity at 2 years
- Diabetic Mouse Wound Model (2020)
- 32 weeks (re-wound at week 20)
- 30 diabetic mice
- Topical hydrogel, daily
- 38% faster wound closure on re-injury (no tolerance)
- None reported
- Demonstrates lack of receptor desensitization
- In Vitro Fibroblast Study (2019)
- 180 days continuous culture
- Human dermal fibroblasts
- 10 nM in culture media
- Sustained collagen I synthesis; no apoptosis increase
- N/A (in vitro)
- Gene expression changes persist without cytotoxicity
- The comparison underscores a critical finding: GHK-Cu long term studies consistently show stable or improving outcomes across extended timelines, with safety profiles that hold under multi-month scrutiny. No published study has documented tolerance, immune rejection, or chronic toxicity in mammals.